Effect on hemoglobin A1C (HBA1C) and body weight after discontinuation of tirzepatide, a novel Glucose-Dependent insulinotropic peptide (GIP) and Glucagon-Like peptide-1 (GLP-1) receptor Agonist: a Single-Center Case Series study
Individuals with a personal or family history of medullary thyroid carcinoma, diagnosed with Multiple Endocrine Neoplasia syndrome type 2, or suffering from severe gastrointestinal disorders or diabetic retinopathy should not take semaglutide
Vial is the total peptide in the vial (in mg)
Conversely, semaglutide markedly improved glucose tolerance, as assessed by oral glucose tolerance test in both dietary conditions (Figures 1D-E)
Start Your Weight Loss Journey Today Ready to discover if GLP-1 weight loss medications are right for you
Medication such as tirzepatide can offer better weight loss outcomes, whereas orlistat or Qsymia would be cheaper options